Bristol-Myers Squibb and Transgene to study new lung cancer regimen

Bristol-Myers Squibb has announced a new partnership with Transgene that will evaluate the benefits of a new combination treatment regimen for lung cancer.

The clinical research collaboration will assess the safety, tolerability and efficacy of Transgene's investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb's approved drug Opdivo, alongside standard chemotherapy.

This regimen will be evaluated in a phase II trial as a first-line treatment for advanced non-squamous non-small cell lung cancer in patients whose tumors have low or undetectable levels of PD-L1.

Under the terms of the agreement, Transgene will act as the sponsor of the trial, with Bristol-Myers Squibb providing access to Opdivo for use in the study.

TG4010 has already shown promising results in combination with chemotherapy in a large phase IIb trial called TIME, and it is hoped that a triple combination regimen could also be beneficial.

Dr Fouad Namouni, head of oncology development at Bristol-Myers Squibb, said: "We are building on our leadership in immuno-oncology with potential combinations of therapies that may help advance new therapeutic approaches for patients in need of better options."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.